Cesca Therapeutics, Inc. (NASDAQ: KOOL) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. SNNLive spoke with Kenneth Harris, President of Cesca Therapeutics Inc. at the Healthcare Media Day 2015 in San Francisco, CA.
In this interview, Mr. Harris and our host begin with an overview of Cesca Therapeutics, which as he states, “came together as a merger of two companies,” and, “we’re focused in cardiovascular and orthopedic clinical development.” Mr. Harris expands by discussing the areas of treatment that Cesca is focusing on, “we’re focused on critical limb ischemia, which is our late-stage development product, planning to move into pivotal phase 3 trials in the next couple of months.”
For more information about Cesca Therapeutics, Inc., go check out their website at: www.CescaTherapeutics.com
© 2017 Stock News Now
Supported by Superior Web Solutions